title: Third allogeneic stem cell transplantation (SCT) using unrelated cord blood for relapsed acute leukemia after second allogeneic SCT.
abstract: We analyzed the results of third allogeneic stem cell transplantation (SCT3) using single-unit unrelated cord blood (CB) in seven adult patients with relapsed acute leukemia after second allogeneic stem cell transplantation (SCT2). The median age at SCT 3 was 44 years (range 20-58 years). The patients had de novo acute myeloid leukemia (AML) (n = 4), secondary AML following myelodysplastic syndrome (n = 2), and acute lymphoblastic leukemia (n = 1). Four patients received myeloablative conditioning, and three received reduced-intensity conditioning. All but one patient had myeloid reconstitution with remission, but five patients relapsed even after SCT3. However, one patient is alive and disease-free 6 years after SCT3, which is the longest remission duration among three allogeneic SCTs she received. Furthermore, actual survival after relapse of SCT 2 was significantly better for patients who received SCT3 compared with institutional control patients who never received SCT3 (P < 0.001). These results suggest that the use of CB may allow the opportunity to perform SCT3 in patients who have experienced relapsed leukemia without donors, and SCT3 with CB may offer the chance of durable remission for selected patients with relapsed acute leukemia.
authors: Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan, tkonuma@ims.u-tokyo.ac.jp.
authors: Takaaki
authors: T
authors: Konuma
authors: Seiko
authors: S
authors: Kato
authors: Jun
authors: J
authors: Ooi
authors: Yasuhiro
authors: Y
authors: Ebihara
authors: Shinji
authors: S
authors: Mochizuki
authors: Maki
authors: M
authors: Oiwa-Monna
authors: Arinobu
authors: A
authors: Tojo
authors: Satoshi
authors: S
authors: Takahashi
mesh_terms: D000328:Adult; D036101:Cord Blood Stem Cell Transplantation / Q000379:methods; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000150:complications / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000150:complications / Q000628:therapy; D009364:Neoplasm Recurrence, Local / Q000150:complications / Q000628:therapy*; D033581:Stem Cell Transplantation / Q000379:methods; D016019:Survival Analysis; D014184:Transplantation, Homologous; D055815:Young Adult
references: Leuk Lymphoma. 2013 Jan;54(1):105-9
references: 22721498
references: Case Rep Hematol. 2014;2014:918708
references: 24660078
references: Hematology Am Soc Hematol Educ Program. 2009;:414-8
references: 20008227
references: Bone Marrow Transplant. 2004 Oct;34(8):721-7
references: 15322568
references: Bone Marrow Transplant. 2005 Feb;35(3):261-4
references: 15558039
references: Bone Marrow Transplant. 2009 Nov;44(10):661-6
references: 19802029
references: J Clin Oncol. 2001 Aug 15;19(16):3675-84
references: 11504749
references: Bone Marrow Transplant. 1997 Mar;19(5):461-6
references: 9052912
references: J Clin Oncol. 2013 Sep 10;31(26):3259-71
references: 23918951
references: Leuk Res. 2009 Jun;33(6):840-2
references: 18995897
references: Biol Blood Marrow Transplant. 2009 Apr;15(4):483-9
references: 19285636
references: J Clin Oncol. 1993 Feb;11(2):304-13
references: 8426208
references: Br J Haematol. 2001 Dec;115(3):622-9
references: 11736947
references: Int J Hematol. 2009 Apr;89(3):374-82
references: 19291359
references: Blood. 2007 Feb 1;109(3):1322-30
references: 17038536
references: Bone Marrow Transplant. 2013 Mar;48(3):452-8
references: 23208313
references: Intern Med. 2012;51(20):2943-7
references: 23064573
references: Biol Blood Marrow Transplant. 2014 Aug;20(8):1150-5
references: 24727335
references: Blood. 2004 Dec 1;104(12):3813-20
references: 15280199
references: Acta Haematol. 2009;122(4):185-92
references: 19887774